Introduction
============

Hepatocellular carcinoma (HCC) is the second leading cause of cancer-related death in Taiwan and worldwide in 2016 and 2015.[@b1-tcrm-14-1157] Most HCCs are diagnosed at an advanced stage, and surgical complete resection is not suitable, in particular for patients with portal vein tumor thrombus (PVTT).[@b2-tcrm-14-1157]--[@b4-tcrm-14-1157] Those with PVTT are at an increased risk of liver failure by wide dissemination of tumor throughout the liver.[@b5-tcrm-14-1157],[@b6-tcrm-14-1157] The prognosis is extremely poor, and the patients have lower tolerance to treatment with limited survival about only several months.[@b7-tcrm-14-1157],[@b8-tcrm-14-1157]

In recent years, various treatment modalities such as transarterial chemoembolization (TACE), hepatic arterial infusion chemotherapy (HAIC), three-dimensional radiotherapy (3D-RT), stereotactic body radiotherapy (SBRT), immunotherapy, and sorafenib have been tried for the treatment of advanced HCC with PVTT, but the optimal treatment strategy remains controversial. Recently, some studies reported that TACE or repetitive HAIC in advanced HCC has achieved favorable results.[@b9-tcrm-14-1157]--[@b13-tcrm-14-1157] With the advances in radiation technology, 3D-RT or SBRT has been used for advanced HCC with the benefit of using higher radiation doses directed at the tumor that spare the organ at risk from substantial radiation.[@b14-tcrm-14-1157],[@b15-tcrm-14-1157] Many studies have reported that 3D-RT plus TACE or HAIC showed good tumor and PVTT response than TACE or HAIC used alone.[@b16-tcrm-14-1157]--[@b21-tcrm-14-1157] However, some studies indicated that adding RT to TACE or HAIC does not improve survival but increases the incidence of adverse events compared with TACE or HAIC alone.[@b19-tcrm-14-1157],[@b22-tcrm-14-1157] Therefore, the purpose of this network meta-analysis was to evaluate the efficacy and safety of these regimens in terms of disease control rate (DCR) and severe adverse events in advanced HCC patients with PVTT.

Methods
=======

Literature search
-----------------

We conducted this network meta-analysis in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses statement.[@b23-tcrm-14-1157] A systematic literature search of the PubMed and Cochrane Library from inception through November 2017 was performed. The search strategy was based on combinations of the following keywords: ("advanced" \[Mesh\]) AND ("hepatomas" or "liver cell carcinomas" \[MeSH terms\]) OR ("hepatocellular carcinoma" \[MeSH terms\] AND \[all fields\]) AND ("clinical study" \[publication type\] OR "cohort as topic" \[MeSH terms\]) AND ("sorafenib" or "Nexavar") AND ("hepatic arterial infusion chemotherapy" or "HAIC") AND ("TACE" or "transarterial chemoembolization") AND (" radiotherapy" or "stereotactic body or SBRT"). In addition, we manually examined the titles of all references within the selected articles to identify other potentially appropriate articles. Two authors (AC and HL) evaluated the titles and abstracts independently. Disagreements were discussed until consensus was reached. Letters to the editor, case reports, nonrandomized trials, animal studies, editorials, and posters were excluded. The language was also restricted to English.

Study selection criteria
------------------------

The selected studies had to meet the following criteria: 1) nonrandomized or cohort studies; 2) included patients with pathologically proven advanced inoperable HCC with PVTT; 3) detailed data on method, characteristics of patient population, tumor response rates, adverse events, and overall survival; 4) compared at least two arms that consisted of the abovementioned interested regimens; and 5) tumor response rates were defined and evaluated based on the comparison of abdominal computed tomography or magnetic resonance imaging before and after treatment according to the modified Response Evaluation Criteria in Solid Tumors (RECIST) guidelines for HCC.[@b24-tcrm-14-1157] A complete response (CR) was defined as disappearance of all target/nontarget lesions after treatment; partial response (PR) was defined as follows: the size of lesion decreased 30% in the sum of the longest diameters of the target lesions; progressive disease (PD) was defined as follows: the size of lesion increased 20% in the sum of the longest diameters of the target lesions; stable disease (SD) was defined as not meeting the criteria of CR, PR, or PD, all other variations.

Data extraction and quality assessment
--------------------------------------

Two authors (AC and HL) independently reviewed and screened all eligible studies based on the study selection criteria detailed above. The following data were extracted and summarized in a standardized table, including the study's first author; characteristics of the population; and data to define advanced HCC, interventions, and outcomes such as overall survival and tumor response in terms of DCR and adverse events ([Table 1](#t1-tcrm-14-1157){ref-type="table"}). The assessment primary outcome in this study was DCR. The secondary outcomes were median overall survival and grade 3 or 4 adverse events. The DCR was defined as the percentage of a CR, PR, or SD for each study according to the modified RECIST guidelines.

The quality of the included studies was assessed using the Cochrane risk of bias tool (Version 5.1.0). Each study was evaluated independently by two authors explicitly with the following judgment system: low risk of bias, high risk of bias, or unclear (either lack of information or uncertainty for bias).[@b25-tcrm-14-1157] The quality of evidence in these studies was evaluated by using the Grading of Recommendations, Assessment, Development and Evaluations (GRADE) profiler (GRADEpro) software, Version 3.2 (the Cochrane Information Management System).[@b26-tcrm-14-1157]

Network meta-analysis
---------------------

We conducted a network meta-analysis to compare the outcomes among the 15 studies for advanced HCC with PVTT, which included direct (ie, head-to-head) and indirect treatment comparisons.[@b19-tcrm-14-1157]--[@b22-tcrm-14-1157],[@b27-tcrm-14-1157]--[@b37-tcrm-14-1157] We extracted the DCR and grade 3 or 4 adverse events data directly from the studies to calculate the odds ratios (ORs) with 95% confidence intervals (95% CIs). A network meta-analysis was conducted using WinBUGS within Microsoft Excel (Microsoft Corporation, Redmond, WA, USA) to synthesize direct and indirect treatment regimens simultaneously and summarize all possible pairwise comparisons between the various regimens as a league table.[@b38-tcrm-14-1157],[@b39-tcrm-14-1157] The probability of each treatment for a particular outcome would be calculated and ranked first, second, third, etc. by the surface under the cumulative ranking (SUCRA) curve.[@b40-tcrm-14-1157] The larger SUCRA number represented the best treatment regimens among the network meta-analysis.

Statistical analysis
--------------------

The heterogeneity was assessed with the I^2^ statistic using Review Manager (RevMan) software, Version 5.3.5 (The Cochrane Collaboration, Copenhagen, Denmark).[@b45-tcrm-14-1157] I^2^ statistics were used to measure statistical heterogeneity. I^2^ is the percentage of total variation attributable to differences observed between the studies rather than sampling error. It is also an intuitive and a simple expression of the inconsistency of studies' results. I^2^ values \<25% and \>75% were regarded as indications of low and high heterogeneity, respectively.[@b41-tcrm-14-1157] If significant heterogeneity existed, a fixed-effect statistical model would be used.

The assessment of network inconsistency was conducted by comparing the deviance residuals and deviance information criterion statistics in fitted consistency and inconsistency models to identify inconsistency presented in any loops in the treatment network.[@b42-tcrm-14-1157] Inconsistency is caused by imbalances in effect modifiers from study to study, particularly in the direct and indirect evidence. We could select the points on the inconsistency plot to identify which study and treatment contributed to the network inconsistency.

The sensitivity analysis was performed to test the robustness of the network analysis by repeating the main computations using a random-effects model.

Results
=======

Characteristics of the selected studies
---------------------------------------

A total of 222 relevant studies were identified through the comprehensive search. After all titles and abstracts were reviewed, 116 studies were excluded because of not matching with the selection criteria. After screening of full-length articles, we found 15 studies that matched the inclusion criteria.[@b19-tcrm-14-1157]--[@b22-tcrm-14-1157],[@b27-tcrm-14-1157]--[@b37-tcrm-14-1157] Twelve studies were retrospective cohort study, and three studies were prospective studies.[@b22-tcrm-14-1157],[@b28-tcrm-14-1157],[@b32-tcrm-14-1157] All the studies were conducted in Asia, except two studies were in Austria and the USA. [Table 1](#t1-tcrm-14-1157){ref-type="table"} presents the study characteristics. [Figure 1](#f1-tcrm-14-1157){ref-type="fig"} is the flow diagram of the systematic literature search and selection. A total of 2,359 patients were included in the network meta-analysis, among which 1,061 patients and 319 patients were treated with TACE and HAIC alone.

Quality assessment
------------------

[Figure 2](#f2-tcrm-14-1157){ref-type="fig"} summarizes the risk of bias for the 15 selected studies. All the studies selected exposed cohorts from the same population. Ten studies (66.7%) showed a high risk of bias for the item of comprehensive matching or adjustment for those prognostic variables. Of these 10 studies, five studies (33.3%) showed a high risk of bias for assessment criteria 2 (assessment of exposure) and five studies (33.3%) showed a high risk of bias for the assessment of the presence or absence of prognostic factors. Therefore, the quality of evidence was assessed for the individual studies as moderate[@b22-tcrm-14-1157],[@b33-tcrm-14-1157],[@b34-tcrm-14-1157],[@b36-tcrm-14-1157],[@b37-tcrm-14-1157] or high[@b12-tcrm-14-1157]--[@b20-tcrm-14-1157],[@b27-tcrm-14-1157]--[@b32-tcrm-14-1157] according to the GRADE method ([Table 1](#t1-tcrm-14-1157){ref-type="table"}).

Network meta-analysis
---------------------

The ranking table in [Figure 3](#f3-tcrm-14-1157){ref-type="fig"} shows the comparison of the efficacy of all treatment regimens against each other in terms of DCR in treating advanced HCC with portal vein invasion. Regimen in the left side was the most effective (OR \>1), and regimen in the right side was the least effective (OR \<1). From the ranking table generated, it was clear that RT plus HAIC would be the most effective in treating patients with advanced HCC and portal vein invasion (OR range: 4.52--6.40; 95% CI =31.29--9.16 and 2.98--14.03), followed by RT plus TACE (OR range: 3.55--5.03, 95% CI =1.38--9.16 and 2.18--11.82). HAIC alone and sorafenib combined with HAIC appeared the least effective, although it still showed significantly increased DCR when compared with other four regimens. We also compared the efficacy of all interested regimens in terms of the median overall survival retrieved from the included studies. RT plus TACE and RT plus HAIC were still the most effective in treating advanced HCC with portal vein invasion ([Figure 4](#f4-tcrm-14-1157){ref-type="fig"}).

The results of SUCRA curve for each treatment in terms of DCR demonstrated the same results that 3D-RT combined with HAIC was the best regimen (SUCRA 0.9337) followed by 3D-RT combined with TACE (SUCRA 0.85). Sorafenib alone was the worst (SUCRA 0.1122) regimen for mHCC patients with portal vein invasion ([Figure 5](#f5-tcrm-14-1157){ref-type="fig"}).

In the safety analysis, retrieving grade 3 or 4 adverse events from all included studies was limited. From the ranking table generated, it was found that regimens with OR \<1 would be the safer regimens when compared with every other modalities ([Figure 6](#f6-tcrm-14-1157){ref-type="fig"}). Then, SBRT, sorafenib, or TACE used alone had significant fewer severe adverse events as compared to other regimens. In the subgroup analysis, the severe hematological adverse events (grade 3 or 4) occurred in patients treated with 3D-RT combined with TACE or HAIC and TACE or HAIC used alone were leucopenia and thrombocytopenia. Hand--foot syndrome was the most common severe adverse event in sorafenib regimen ([Table 1](#t1-tcrm-14-1157){ref-type="table"}). However, three studies did not have grade 3 or 4 adverse events data available for analysis.[@b30-tcrm-14-1157]--[@b32-tcrm-14-1157]

Assessment of inconsistency and heterogeneity
---------------------------------------------

The assessment of inconsistency in the network meta-analysis was presented by the inconsistency plot in fixed-effects model. From the inconsistency plot in [Figure 7](#f7-tcrm-14-1157){ref-type="fig"}, it was found that all studies were along with the line of equality, which may indicate that the effect modifiers are more evenly balanced across the network; it is more likely to be no potential inconsistency between different treatment modalities.

From the results of pooled data for heterogeneity (I^2^), it was found that between-studies variation within compared treatment modalities was 19%. In the subgroup analysis of included treatment regimens, the heterogeneity (I^2^) values for TACE plus sorafenib versus TACE or sorafenib alone and HAIC + RT versus HAIC alone were 20% and 19%, respectively, which indicated low heterogeneity (I^2^\<25%). The heterogeneity (I^2^) for other regimens was 0% ([Table 1](#t1-tcrm-14-1157){ref-type="table"}).

The sensitivity analysis showed that the network results of the random-effects model were consistent with that of the fixed-effects model. The pooled OR remained unchanged in heterogeneity (I^2^=19) and slightly changed in OR (1.96 \[1.51, 2.56\] in random-effects model; 1.99 \[1.58, 2.50\] in fixed-effects model).

Discussion
==========

To the best of our knowledge, this is the first network meta-analysis to compare the efficacy and safety of the treatment regimens in patients with advanced HCC and portal vein invasion. PVTT is a well-known poor prognostic factor for HCC patients, whose median survival time was only 2.7 months.[@b43-tcrm-14-1157] In this network meta-analysis, we collected the direct and indirect comparative data and assessed the tumor control rate, median survival rate, and severe adverse events in advanced HCC patients with PVTT undergoing different treatment modalities. The pooled results demonstrated that, in patients with advanced HCC with PVTT, those who were treated with local control combination regimens, such as 3D-RT plus TACE (OR~RT\ +~ TACE =3.55--5.03; 95% CI =1.38--9.16 and 2.98--11.82) and 3D-RT plus HAIC (OR~RT\ +\ HAIC~ =4.52--6.40; 95% CI =31.29--9.16 and 2.98--14.03), could reach significantly higher PVTT and tumor response as well as better median overall survival (OR~RT\ +\ TACE~ =2.90--3.47; 95% CI =2.02--4.17 and 1.45--8.25; OR~RT\ +\ HAIC~ =3.44; 95% CI =1.58--7.55) compared with those other six regimens. The combination regimens were well tolerated with statistically nonsignificant and significant severe grade 3 or 4 adverse events (OR~TACE\ +\ Sorafenib~ =0.32; 95% CI =0.07-1.34; OR~RT\ +\ HAIC~ =0.91; 95% CI =0.44-1.89; OR~RT\ +\ TACE~ =0.07; 95% CI =0.01--0.3). Based on these results, it was suggested that either TACE or HAIC in combination with 3D-RT is a better choice for advanced HCC patients with PVTT. No network meta-analysis has previously been published focusing on comparing different treatment modalities for patients with advanced HCC and portal vein invasion. Therefore, we compared the results of HAIC or TACE or sorafenib combined with 3D-RT with those from conventional meta-analyses published recently. We found that the results in our analysis may be considered as a further evidence to support the previous three conventional meta-analyses because the conventional meta-analysis conducted by Zhang et al[@b45-tcrm-14-1157] and Huo and Eslick[@b44-tcrm-14-1157] did not include all patients with portal vein invasion and the outcomes were only presented in terms of objective response rate. Thus, their results may be overestimation.[@b44-tcrm-14-1157],[@b45-tcrm-14-1157] Only the meta-analysis conducted by Zhao et al was similar to our study to enroll patients with advanced HCC with portal vein invasion.[@b46-tcrm-14-1157]

Various treatment modalities have been tried to treat advanced HCC patients with PVTT, but the optimal treatment remains controversial. Surgical resection has been considered as the first preferred modality for highly selected patients with reserved liver function and localized PVTT in the distal branch. TACE is considered as a first-line treatment for patients with HCC, Barcelona Cancer Clinic Liver Cancer (BCLC) stage B with an excellent liver function, and asymptomatic multinodular tumors without macroscopic vascular invasion or extrahepatic spread. HAIC has been used for advanced HCC without distant metastasis with improved survival in Asian countries, such as Japan, Korea, and China. SBRT is a newer treatment modality for patients with local-ized HCC and not eligible to TACE.[@b47-tcrm-14-1157] 3D-RT and SBRT are emerging as practical treatment modalities for localized HCC. Although the BCLC guideline recommended sorafenib as the standard systematic therapy for advanced HCC patients, and sorafenib alone has limited efficacy for HCC patients with limiting extrahepatic spread. With the advances in the technology of radiation therapy, SBRT is a treatment option with local control rates of 75% to 100% at 1--2 years of survival.[@b48-tcrm-14-1157],[@b49-tcrm-14-1157] Recently, many studies demonstrated that the combination of 3D-RT or SBRT with HAIC or TACE and TACE combined with sorafenib to treat PVTT were superior to any single treatment option.[@b44-tcrm-14-1157] The mechanisms of the combination of radiotherapy (SBRT or 3D-RT) and TACE may involve 1) the reduction of the radiation target volume and the increase of radiation dose precisely delivered to the target lesion and thus sparing uninvolved normal liver tissue; 2) the administration of RT after TACE may contribute to killing or inhibiting any residual tumor cells after TACE;[@b31-tcrm-14-1157],[@b36-tcrm-14-1157] and 3) PVTT is sensitive to RT, which can boost the treatment responses of tumors and PVTT.[@b50-tcrm-14-1157],[@b51-tcrm-14-1157] As for the mechanisms of combination of TACE and sorafenib, this multimodality may involve the embolization of the hepatic artery and reduce the portal vein blood supply to HCC.[@b52-tcrm-14-1157],[@b53-tcrm-14-1157] Sorafenib is an orally active Raf kinase inhibitor with effects on tumor cell proliferation and tumor angiogenesis that acts by inhibiting the serine--threonine kinases Raf-1 and B-Raf. It also inhibits vascular endothelial growth factor receptors 1, 2, and 3; platelet-derived growth factor receptor β; and receptor tyrosine kinase receptor tyrosine kinases.[@b54-tcrm-14-1157]

The network meta-analysis is a useful method for incorporating information from both direct and indirect treatment comparisons in a network of studies using novel statistical methods. It can help us to make a quantitative comparison of the efficacy and safety of various competing treatments in a single analysis.

Study limitation
================

The limitations of our network meta-analysis should be considered in the interpretation of the results. First, the baseline characteristics of the enrolled studies may influence the heterogeneity and the results, such as the dose of HAIC used which depends on patients' body surface area, the location of portal vein thrombus, type of tumor, and the primary tumor size, and there were slightly differences between the studies and may be confounding factor. Second, selection bias resulting from cohort data because patients or clinical investigators may select treatment modalities depending on patients' physical condition or investigator's decision. Third, the small sample size of some studies may cause overestimation of the outcomes. However, our study has advantages that 1) the selected patients had mHCC with portal vein invasion, which may reduce heterogeneity or inconsistency and 2) the primary outcome is more comprehensive than the published conventional meta-analysis.

Conclusion
==========

The network meta-analysis provided evidence that the combination of HAIC or TACE or sorafenib with 3D-RT improved survival and better outcome. Future randomized controlled trials are needed to confirm the advantages of combined therapy of interested modalities over those modalities used alone for mHCC with portal vein invasion.
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![Comparisons of efficacy in terms of disease control rate in advanced HCC scheme.\
**Note:** The numbers in bold indicate OR and 95% CI are significant.\
**Abbreviations:** HAIC, hepatic arterial infusion chemotherapy; OR, odds ratio; SBRT, stereotactic body radiotherapy; TACE, transarterial chemoembolization; RT, radiotherapy.](tcrm-14-1157Fig3){#f3-tcrm-14-1157}

![Comparisons of efficacy in terms of median OS in advanced HCC.\
**Note:** The numbers in bold indicate OR and 95% CI are significant.\
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![Rankogram of interested treatment modality.\
**Abbreviations:** HAIC, hepatic arterial infusion chemotherapy; SBRT, stereotactic body radiotherapy; TACE, transarterial chemoembolization; RT, radiotherapy.](tcrm-14-1157Fig5){#f5-tcrm-14-1157}

![Comparison of adverse events for regimens in advanced HCC OR (95% CI).\
**Note:** The numbers in bold indicate OR and 95% CI are significant.\
**Abbreviations:** CI, confidence interval; HAIC, hepatic arterial infusion chemotherapy; OR, odds ratio; SBRT, stereotactic body radiotherapy; TACE, transarterial chemoembolization; RT, radiotherapy.](tcrm-14-1157Fig6){#f6-tcrm-14-1157}
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###### 

Baseline characteristics of studies included in the network meta-analysis

  Study and treatment                                                                          Study quality   Study design          Propensity score matching   Child--Pugh score                 ECOG PS                                         Vascular invasion                Serum AFP ≥400 ng/mL (n)         End point outcome used   Toxicity ≥ grade 3                                                                    I^2^
  -------------------------------------------------------------------------------------------- --------------- --------------------- --------------------------- --------------------------------- ----------------------------------------------- -------------------------------- -------------------------------- ------------------------ ------------------------------------------------------------------------------------- ------
  **TACE** + **sorafenib vs TACE or sorafenib alone**                                                                                                                                                                                                                                                                18%                                                                                                            
   1. Choi et al,[@b27-tcrm-14-1157] Korea; TACE + sorafenib (=164); sorafenib alone (n=191)   High            Retrospective         Yes                         A/B: 119/45; A/B: 136/55          NA                                              PVTT + extrahepatic meta         83; 104                          OS, DCR                  Leucopenia: 6 vs 3; hand--foot: 29 vs 23                                              
   2. Bai et al,[@b28-tcrm-14-1157] China; TACE + sorafenib (=82); TACE alone (n=146)          High            Prospective non-RCT   Yes                         A/B: 63/19; A/B: 163/59           0/1/2/3: 30/38/12/1/1; 0/1/2/3: 85/119/18/0/0   MVI + extrahepatic metastasis    NA                               OS, DCR                  Hand--foot: 2 vs 0; diarrhea: 4 vs 0                                                  
  **TACE vs sorafenib alone**                                                                                                                                                                                                                                                                                                                                                                                                       
   3. Pinter et al,[@b29-tcrm-14-1157] Austria; TACE alone (n=34); sorafenib alone (n=63)      High            Retrospective         No                          A/B: 20/14; A/B: 28/35            0/≥1: 9/25; 0/≥1: 21/42                         MVI + extrahepatic metastasis    8; 19                            OS, DCR                  Leucopenia: 2 vs 1; hand--foot: 0 vs 2                                                
  **TACE** + **3D-RT vs TACE**                                                                                                                                                                                                                                                                                                                                                                                                      0%
   4. Li et al,[@b30-tcrm-14-1157] China; TACE + RT (n=108); TACE alone (n=108)                High            Retrospective         Yes                         A/B: 102/6; A/B: 105/3            NA                                              PVTT + extrahepatic metastasis   66; 61                           OS, DCR                  NA                                                                                    
   5. Lu et al,[@b31-tcrm-14-1157] China; TACE + RT (n=30); TACE alone (n=33)                  High            Retrospective         No                          A/B: 20/10; A/B: 21/12            NA                                              PVTT + extrahepatic meta         12; 11                           OS, DCR                  NA                                                                                    
   6. Koo et al,[@b32-tcrm-14-1157] Korea; TACE + RT (n=42); TACE alone (n=29)                 High            Prospective           No                          A/B: 26/16; A/B: 17/12            0--2                                            IVCTT                            ≤1,000 ng/mL; 22; 14             OS, DCR                  NA                                                                                    
  **HAIC** + **3D-RT vs HAIC alone**                                                                                                                                                                                                                                                                                                                                                                                                17%
   7. Chuma et al,[@b21-tcrm-14-1157] Japan; HAIC + RT (n=20); HAIC alone (n=20)               Moderate        Retrospective         No                          A/B: 15/5; A/B: 13/7              NA                                              PVTT                             NA                               OS, DCR                  Leucopenia: 3 vs 2                                                                    
   8. Fujino et al,[@b19-tcrm-14-1157] Japan; HAIC + RT (n=41); HAIC alone (n=42)              High            Retrospective         No                          A/B/C: 19/14/8; A/B/C: 14/18/10   0/1: 37/4; 0/1: 35/7                            PVTT                             464; 1,742                       OS, DCR                  Leucopenia: 5 vs 6; thrombocytopenia: 5 vs 6                                          
   9. Katamura et al,[@b22-tcrm-14-1157] Japan; HAIC + RT (n=16); HAIC alone (n=16)            Moderate        Prospective           No                          A/B: 12/4; A/B: 13/3              NA                                              PVTT                             184.8; 586.7                     OS, DCR                  Leucopenia: 9 vs 3; thrombocytopenia: 6 vs 5                                          
   10. Onishi et al,[@b20-tcrm-14-1157] Japan; HAIC + RT (n=33); HAIC alone (n=34)             High            Retrospective         No                          B: 16; B: 16                      NA                                              PVTT                             575; 399                         OS, DCR                  Blood bile increase: 3 vs 2; leucopenia: 15 vs 2                                      
  **Sorafenib alone vs HAIC alone**                                                                                                                                                                                                                                                                                  0%                                                                                                             
   11. Jeong et al,[@b33-tcrm-14-1157] Korea; HAIC alone (n=21); sorafenib alone (n=20)        High            Retrospective         No                          A/B: 10/11; A/B: 14/6             1/2: 19/2; 1/2: 16/4                            PVTT + extrahepatic meta         12; 13                           OS, DCR                  Neutropenia: 5 vs 0; thrombocytopenia: 6 vs 0; hand--foot: 0 vs 2                     
   12. Kawaoka et al,[@b34-tcrm-14-1157] Japan; HAIC alone (n=136); sorafenib alone (n=41)     Moderate        Retrospective         No                          A: 136; A: 41                     NA                                              MVI                              Median: 415.3; 136               OS, DCR                  Liver failure: 3 vs 0; hand--foot: 0 vs 2                                             
   13. Song et al,[@b35-tcrm-14-1157] Japan; HAIC alone (n=136); sorafenib alone (n=41)        High            Retrospective         No                          A/B: 45/4; A/B: 47/13             NA                                              PVTT + extrahepatic meta         Serum AFP ≥200 ng/mL; 32 vs 51   OS, DCR                  Hematology[a](#tfn1-tcrm-14-1157){ref-type="table-fn"}: 106 vs 0; diarrhea: 0 vs 13   
  **SBRT** + **TACE vs SBRT**                                                                                                                                                                                                                                                                                                                                                                                                       0%
   14. Kang et al,[@b36-tcrm-14-1157] China; SBRT + TACE (n=71); SBRT (n=30)                   Moderate        Retrospective         No                          A/B: 48/19; A/B: 24/11            NA                                              PVTT                             27; 9                            OS, DCR                  NA                                                                                    
   15. Sapir et al,[@b37-tcrm-14-1157] USA TACE (n=84); SBRT (n=125)                           Moderate        Retrospective         Yes                         A: 84; 125                        \<2: 142/95; ≤2: 24; 25                         PVTT                             NA                               OS, DCR                  Hypervolemia: 3 vs 1; GI and biliary: 2 vs 7                                          
  **Pooled data**                                                                                                                                                                                                                                                                                                                                                                                                                   19%

**Note:**

Hematology in HAIC group: leucopenia (36), neutropenia (46), anemia (72), and thrombocytopenia (56).

**Abbreviations:** AFP, alpha-fetoprotein; DCR, disease control rate; ECOG PS, Eastern Cooperative Oncology Group Performance Status; GI, gastrointestinal; HAIC, hepatic arterial infusion chemotherapy; IVCTT, inferior vena cava tumoral thrombosis; MVI, macrovascular invasion; OS, overall survival; PVTT, portal vein tumor thrombus; RCT, randomized controlled trial; SBRT, stereotactic body radiotherapy; TACE, transarterial chemoembolization; 3D-RT, three-dimensional radiotherapy; NA, not available; RT, radiotherapy.
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